Patient-Focused Drug Development High On Industry’s List Of PDUFA VI Tweaks

BIO and PhRMA want patient input gathered through a more structured and data-driven process than the current disease area meetings under PDUFA V, which are “anecdotal” in nature; National Organization for Rare Disorders seeks an interactive portal between patient community and FDA reviewers.